Arabic Arabic English English French French German German
dark

Blade Therapeutics Announces FDA Activation of IND Application to Investigate Cudetaxestat, a Non-Competitive Autotaxin Inhibitor, in Idiopathic Pulmonary Fibrosis (IPF)

Blade Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has activated the Company’s Investigational New Drug (IND) application to investigate cudetaxestat in IPF. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

MassBio Industry Snapshot Predicts 40,000 New Biopharma Jobs Over the Next 10 Years

Next Post

Rapid Dose Therapeutics Reports Fiscal Year 2021 Financial Results

Related Posts
Total
0
Share